Related Experiment Video
Updated: May 10, 2026
09:30
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
Treatment under DOTS
Nitin Rathi1, Rajat Jhamb, Pushpender Verma
1Respiratory Disease & Internal Medicine, University College of Medical Sciences and GTB Hospital, Dilshad Garden, Shahdra, Delhi.
The Journal of Communicable Diseases
|June 22, 2013
Summary
Patient delay is the primary cause of delays in tuberculosis treatment within Directly Observed Treatment, Short-course (DOTS) programs. Addressing patient reporting times is crucial for improving tuberculosis care efficiency.
Area of Science:
- Public Health
- Infectious Diseases
- Tuberculosis Research
Background:
- Tuberculosis (TB) remains a significant global health challenge.
- Delays in diagnosis and treatment contribute to disease progression and transmission.
- Directly Observed Treatment, Short-course (DOTS) is a key strategy for TB control.
Purpose of the Study:
- To investigate the types and extent of delays in the TB care cascade within DOTS centers.
- To identify the primary sources of delay in patient management.
- To provide insights for optimizing TB treatment initiation and patient flow.
Main Methods:
- Prospective study conducted at three DOTS cum Microscopy Centres.
- Utilized a pre-tested questionnaire administered to patients at the start of treatment.
- Included 311 patients to analyze different types of treatment delays.
Main Results:
- 158 out of 311 patients experienced various delays.
- Patient delay was the most significant factor, accounting for 43.08% of cases.
- Diagnosis delay was minimal (7.34%), suggesting efficient diagnostic processes.
- Treatment delay was observed in 22.5% of the study population.
Conclusions:
- Patient-related delays in seeking care are the predominant issue in DOTS programs.
- While diagnosis is efficient, late initiation of treatment requires systemic attention.
- Interventions should focus on reducing patient delay to improve TB management outcomes.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...